NanoViricides pan-coronavirus COVID-19 drug candidates highly effective in pre-clinical animal atudies
On Mar. 2, 2021, NanoViricides reported that NV-CoV-2 and NV-CoV-2-R were found to be highly effective in comparison…
On Mar. 2, 2021, NanoViricides reported that NV-CoV-2 and NV-CoV-2-R were found to be highly effective in comparison…
On Mar. 2, 2021, Innovation Pharmaceuticals reported that eight sites were participating in the Companyï¾’s international Phase 2…
On Mar. 2, 2021, Cerecor announced final efficacy data including 60-day mortality from their completed US-based, multi-center (10…
On Mar. 2, 2021, the Biden Administration has helped forge a historic manufacturing collaboration between two of the…
On Mar. 1, 2021, the WHO announced that the first COVID-19 vaccination campaigns in Africa using COVAX doses…
On Mar. 1, 2021, Colombia became the first country in the Americas to receive COVID-19 vaccines through the…
On Mar. 1, 2021, Quidel announced that it had received an Emergency Use Authorization (EUA) from the FDA,…
On Mar. 1, 2021, a study from Washington University School of Medicine in St. Louis provided evidence that…
On Feb. 28, 2021, after a transparent evidence-based review of all available data, the Advisory Committee on Immunization…
On Feb. 28, 2021, Johnson & Johnson announced that the U.S. Centers for Disease Control and Preventionï¾’s (CDC)…
On Feb. 27, 2021, Johnson & Johnson announced that the U.S. Food and Drug Administration (FDA) had issued…
On Feb. 26, 2021, Innovation Pharmaceuticals announced that after an interim review, by an independent Data Monitoring Committee…
On Feb. 26, 2021, Novavax and Takeda Pharmaceutical announced an exclusive license agreement for Takeda’s development, manufacturing and…
On Feb. 26, 2021, Johnson & Johnson announced that the FDA Vaccines and Related Biological Products Advisory Committee…
On Feb. 26, 2021, Regeneron announced the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use…
On Feb. 25, 2021, the U.S. Food and Drug Administration announced that it was allowing undiluted frozen vials…
On Feb. 25, 2021, Altimmune announced that it had commenced enrollment in a Phase 1 clinical trial of…
On Feb. 25, 2021, Chimerix reported topline results from the first cohort of its randomized, double-blind, placebo-controlled Phase…
On Feb. 25, 2021, Pfizer and BioNTech announced they had begun an evaluation of the safety and immunogenicity…
On Feb. 25, 2021, Regeneron announced changes to the phase 3 trial assessing investigational REGEN-COVï¾™ (casirivimab with imdevimab)…
On Feb. 24, 2021, scientists at the University of Oxford reported that overall deaths did not increase in…
On Feb. 24, 2021, Ghana became the first country outside India to receive COVID-19 vaccine doses shipped via…
On Feb. 24, 2021, XPhyto announced that it has placed the first order for its rapid point-of-care SARS-CoV-2…
On Feb. 24, 2021, NeuroRx, announced that the phase 2b/3 trial of ZYESAMI for the treatment of Respiratory…
On Feb. 24, 2021, Quest Diagnostics introduced a new COVID-19 testing service that aids in providing insight into…
On Feb. 23, 2021, Cue Health announced that its molecular point-of-care COVID-19 Test had received the CE mark,…
On Feb. 23, 2021, PerkinElmer announced the launch of the PerkinElmerï¾® COVID-19 Antigen Test for the qualitative detection…
On Feb. 22, 2021, Amyris announced highly promising preliminary data in a pre-clinical study of its ribonucleic acid…
On Feb. 22, 2021, Biohaven Pharmaceutical announced that a hyperimmune globulin mimic (HGM) developed with Biohaven’s proprietary MATE…
On Feb. 22, 2021, Novavax announced it had completed enrollment of PREVENT-19, its pivotal Phase 3 study in…